Synthesis and stability test of radiogadolinium(III)-DOTA-PAMAM G3.0-trastuzumab as SPECT-MRI molecular imaging agent for diagnosis of HER-2 positive breast cancer

摘要: Nonivasive diagnosis of cancer can be provided by molecular imaging using hybrid modality to obtain better sensitivity, specificity and depiction localization the disease. In this study, we developed a new agent, radiogadolinium(III)-DOTA-PAMAM G3.0-trastuzumab in form 147Gd-DOTA-PAMAM G3.0-trastuzumab, that both target-specific radiopharmaceutical SPECT as well targeted contrast agent MRI for purpose HER-2 positive breast cancer. 147Gd radionuclide emits γ-rays used modality, but because technical constraint, was simulated its radioisotope, 153Gd. Gd-DOTA complex has also been known good agent. PAMAM G3.0 is useful concentrate compelexes large quantities, thus minimizing number trastuzumab molecules used. Trastuzumab human monoclonal antibody spesifically interact with HER-2. Synthesis initiated conjugating DOTA NHS ester ligand dendrimer. The DOTA-PAMAM produced conjugated molecule labeled Characterization immunoconjugate performed HPLC system equipped SEC. formation indicated shorter retention time (6.82 min) compared (7.06 min). Radiochemical purity >99% after purification process PD-10 desalting column. Radiogadolinium(III)-DOTA-PAMAM compound stable at room temperature 2–8 0C radiochemical 97.6 ± 0.5%–99.1 0.5% 144 h storage.